Acceleron takes a lesson from the giant Belgian blue

The Boston Globe profiles the drug development work of Acceleron, which hopes to develop a therapy that regulates body tissues and systems. To help illustrate its efforts, researchers point to a picture of the Belgian blue, a white bull with enormous muscles. The company believes the same kind of genetics at work in the Belgian blue would help repair the harsh physical damage of such diseases as ALS, muscular dystrophy, and cancer. The company has raised $56 million from top-tier venture capital groups.

- read the Boston Globe article

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.